Adherence level of antihypertensive agents in coronary artery disease

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 74-84

  Perreault, Sylvie ^a   Dragomir, Alice ^a   Roy, Louise ^a   White, Michel ^a   Blais, Lucie ^a   Lalonde, Lyne ^a   Bérard, Anick ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adherence to therapy; Antihypertensive agents; Coronary artery disease

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DRUG INDICATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; QUEBEC; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 72949111814     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03547.x     Document Type: Article

References (44)

1. Fondation des maladies du Coeur du Canada (Fondation des maladies du Coeur du Canada). Le fardeau croissant des maladies cardiovasculaires et des accidents vasculaires cérébraux au Canada, 2003. Report No.: 1-89624-32-4.
2. Writing Group Members Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr., Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics - 2006 update a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 113 : e85 151.
3. Mark DB, Van de Werf FJ, Simes RJ, White HD, Wallentin LC, Califf RM, Armstrong PW for the VIGOUR Group. Cardiovascular disease on a global scale: defining the path forward for research and practice. Eur Heart J 2007 28 : 2678 2684.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 1847.
5. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002 23 : 620 626.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lana F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 952.
7. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994 50 : 272 298.
8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362 : 1527 1535.
9. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003 289 : 2534 2544.
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000 355 : 1955 1964.
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003 362 : 1527 1535.
12. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006 22 : 583 593.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B Management of Arterial Hypertension of the European Society of Hypertension European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 25 : 1105 1187. (Pubitemid 46924065)
14. Rosendorff C, Black H, Cannon C, Gersh B, Gore J, Izzo J, Kaplan N, O'Connor C, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007 115 : 2761 2788.
15. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 43 : 10 17.
16. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997 10 (10 Pt 1 1097 1102.
17. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004 19 : 357 362.
18. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006 185 : 487 489.
19. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death, 9th edn. Publication no PHS 80-1260. Geneva : World Health Organization, 1977.
20. Canada: Supply and Services. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures, 2nd edn. Ottawa, Canada : Statistics Canada Health Division, 1986.
21. RAMQ, Principales variables selon la catégorie de personnes assurées. Studies and Statistics 2005. Available at http://www.ramq.gouv. qc.ca (last accessed 20 September 2006).
22. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 48 : 999 1009.
23. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004 57 : 131 141.
24. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000 53 : 183 194.
25. Monfared A, Rahme E, LeLorier J. Accuracy of ICD-9 diagnosis code '410' to identify episodes of hospitalizations for acute myocardial infarction in RAMQ. First Canadian Therapeutics Congress 2004. Halifax, Canada, 2004.
26. Lubin J, Gail M. Biased selection of controls for case control analyses of cohort studies. Biometrics 1984 40 : 63 75.
27. Peterson AM, Nau DP, Cramer JA, Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 10 : 3 12.
28. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 11 : 449 457.
29. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006 40 : 1280 1288.
30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497.
31. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992 45 : 197 203.
32. Essebag V, Platt R, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005 5 : 5 11.
33. Greene WH. Econometric Analysis, 3rd edn. Upper Saddle River, NJ : Prentice-Hall, 1997 552.
34. Belsley DA, Kuy E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York : John Wiley & Sons, 1981.
35. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007 297 : 177 186.
36. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
37. Smith SC. Current and future directions of cardiovascular risk prediction. Am J Cardiol 2006 97 : 28A 32A.
38. O'Leary DH, Polak JF, Kronmal RA, Manolia TA, Burke GL, Wolfson SK for The Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older patients. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999 340 : 14 22.
39. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992 326 : 381 386.
40. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiology terminology. Am J Epidemiol 1999 149 : 981 983.
41. Daskalopoulo SS, Delaney JAC, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008 29 : 2083 2091.
42. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000 2 : 515 524.
43. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 37 : 846 857.
44. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006 15 : 565 574.